Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder

Autor: Jenny Desantis, Anna Bochicchio, Nina Offermann, Judith Schilling, Frank Matthes, Erich E. Wanker, Stephanie Weber, Paolo Carloni, Sybille Krauss, Giulia Rossetti, Oriana Tabarrini, Kenji Schorpp, Kamyar Hadian, Serena Massari
Rok vydání: 2018
Předmět:
0301 basic medicine
Huntingtin
Physiology
Mutant
01 natural sciences
Biochemistry
genetics [Nerve Tissue Proteins]
Huntingtin Protein
010304 chemical physics
Chemistry
drug effects [Trinucleotide Repeat Expansion]
Nuclear Proteins
genetics [Huntingtin Protein]
General Medicine
Ligand (biochemistry)
Cell biology
Huntington Disease
ddc:540
metabolism [Nuclear Proteins]
genetics [Trinucleotide Repeat Expansion]
congenital
hereditary
and neonatal diseases and abnormalities

Cognitive Neuroscience
In silico
drug effects [Cell Line]
Nerve Tissue Proteins
metabolism [RNA
Messenger]

Cell Line
03 medical and health sciences
drug effects [Nuclear Proteins]
Huntington's disease
0103 physical sciences
mental disorders
medicine
Humans
metabolism [Huntington Disease]
RNA
Messenger

Messenger RNA
metabolism [Nerve Tissue Proteins]
RNA
Cell Biology
medicine.disease
nervous system diseases
drug therapy [Huntington Disease]
030104 developmental biology
pharmacology [Peptides]
metabolism [Huntingtin Protein]
Peptides
Trinucleotide Repeat Expansion
polyglutamine
Zdroj: ACS chemical neuroscience 9(6), 1399-1408 (2018). doi:10.1021/acschemneuro.8b00027
ISSN: 1948-7193
Popis: Expanded CAG trinucleotide repeats in Huntington's disease (HD) are causative for neurotoxicity. The mutant CAG repeat RNA encodes neurotoxic polyglutamine proteins and can lead to a toxic gain of function by aberrantly recruiting RNA-binding proteins. One of these is the MID1 protein, which induces aberrant Huntingtin (HTT) protein translation upon binding. Here we have identified a set of CAG repeat binder candidates by in silico methods. One of those, furamidine, reduces the level of binding of HTT mRNA to MID1 and other target proteins in vitro. Metadynamics calculations, fairly consistent with experimental data measured here, provide hints about the binding mode of the ligand. Importantly, furamidine also decreases the protein level of HTT in a HD cell line model. This shows that small molecules masking RNA-MID1 interactions may be active against mutant HTT protein in living cells.
Databáze: OpenAIRE